Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors

KOC1, TTK, CO16(URLC10), DEPDC1, MPHOSPH1 have been identified using genome-wide expression profile analysis by the use of cDNA microarray in the previous studies. The investigators have determined the HLA-A*2402 restricted epitope peptides respectively derived from KOC1, TTK, CO16(URLC10), DEPDC1, and MPHOSPH1 showed strong INF-gamma production when stimulated with the appropriate targets expressing the appropriate protein and HLA-A*2402. Furthermore, when vaccinated these peptides, specific CTLs were determined after the vaccination. Therefore the investigators focused on the prevention of further expansion of the solid tumors highly expressing these 5 proteins using these 5 peptides.

Inclusion criteria

• clinical diagnosis of unresectable or relapsed gastrointestinal, lung or cervical cancer patients
• performance status 0-1
• age between 20 and 80
• at least 4 weeks after previous therapy
• life expectancy more than 3 months
• permissible bone marrow, liver and renal function
• HLA-A2402
• no viral hepatitis, HIV or HTLV1

Exclusion criteria

• severe underlying disease
• pregnant or lactating women
• active brain metastasis
• uncontrollable infection
• under systemic corticosteroid or immune suppressant treatment
• history of allergy to epitope peptides or IFA